drugset / Trial / NCT05678010
A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer
Phase 1
Active not recruiting
54 enrolled
Memorial Sloan Kettering Cancer Center
AstraZeneca · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to find out whether AZD1390 combined with stereotactic body radiation therapy/SBRT is a safe treatment for people with metastatic solid tumor cancer
Timeline
- Start
- 2023-05-17
- Primary completion
- 2028-05-17
- Completion
- 2028-05-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZD1390 | Small molecule | 20 unknown | — |
| Subject | AZD1390 | Small molecule | 40 unknown | — |
| Subject | AZD1390 | Small molecule | 60 unknown | — |
| Subject | AZD1390 | Small molecule | 80 unknown | — |